Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “outperform” rating reissued by Northland Securities in a research report issued on Tuesday. They presently have a $105.00 price objective on the medical research company’s stock. Northland Securities’ price target would indicate a potential upside of 26.74% from the company’s current price.

EW has been the topic of a number of other research reports. BTIG Research reissued a “buy” rating and set a $110.00 price target on shares of Edwards Lifesciences Corp. in a research report on Friday, October 28th. Wells Fargo & Co. reissued a “buy” rating on shares of Edwards Lifesciences Corp. in a research report on Sunday, September 11th. Evercore ISI reissued a “hold” rating and set a $115.00 price target on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. Royal Bank Of Canada dropped their price target on Edwards Lifesciences Corp. from $130.00 to $123.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 26th. Finally, Leerink Swann reissued a “buy” rating on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-two have issued a buy rating to the company. Edwards Lifesciences Corp. has an average rating of “Buy” and an average target price of $117.28.

Analyst Recommendations for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) opened at 82.85 on Tuesday. Edwards Lifesciences Corp. has a 12 month low of $72.20 and a 12 month high of $121.75. The firm has a 50-day moving average price of $98.42 and a 200-day moving average price of $106.41. The stock has a market cap of $17.71 billion, a price-to-earnings ratio of 32.75 and a beta of 0.71.

Edwards Lifesciences Corp. (NYSE:EW) last released its earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.68. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The business had revenue of $739.40 million for the quarter, compared to analyst estimates of $749.14 million. During the same quarter last year, the firm posted $0.54 earnings per share. The business’s revenue was up 20.1% compared to the same quarter last year. Equities research analysts expect that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/12/01/edwards-lifesciences-corp-ew-stock-rating-reaffirmed-by-northland-securities.html.

In other news, CEO Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $84.67, for a total value of $4,157,297.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Larry L. Wood sold 13,257 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $119.27, for a total value of $1,581,162.39. The disclosure for this sale can be found here. 2.37% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of EW. Bank of Hawaii raised its stake in shares of Edwards Lifesciences Corp. by 0.7% in the third quarter. Bank of Hawaii now owns 2,905 shares of the medical research company’s stock worth $350,000 after buying an additional 20 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Edwards Lifesciences Corp. by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,700 shares of the medical research company’s stock worth $808,000 after buying an additional 20 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences Corp. by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock worth $106,000 after buying an additional 25 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Edwards Lifesciences Corp. by 1.2% in the second quarter. Sigma Planning Corp now owns 2,609 shares of the medical research company’s stock worth $260,000 after buying an additional 31 shares in the last quarter. Finally, Seven Bridges Advisors LLC raised its stake in shares of Edwards Lifesciences Corp. by 1.0% in the third quarter. Seven Bridges Advisors LLC now owns 3,536 shares of the medical research company’s stock worth $426,000 after buying an additional 34 shares in the last quarter. 83.08% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.